Martin Edelman, chair of hematology and oncology at Fox Chase Cancer Center, presented the results of a clinical study testing palbociclib, a drug used to treat breast cancer, in patients with squamous non-small cell lung cancer at the American Society of Clinical Oncology.
A head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive non-small cell lung cancer could help oncologists fine-tune first-line TKI selection beyond what’s been seen in clinical trials alone, according to a study conducted by a team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted.
